Cell Therapy Market to Reach USD 48.98 Billion by 2033 | CAGR 21.4% | North America Leads with 40% Share | Key Players: Gilead Sciences, Iovance, Dendreon, Enzyvant, CellTrans, Gamida Cell

Cell Therapy Market Size

The global Cell Therapy Market reached US$ 6.52 Billion in 2024 and is projected to reach US$ 48.98 Billion by 2033, growing at a CAGR of 21.4% during the forecast period 2025-2033.

The market growth is driven by increasing research and development activities for novel cell therapies, rising regulatory support and approvals, and growing demand for alternatives to traditional drugs in treating life-threatening chronic diseases. Technological advancements and the development of novel delivery methods further support market expansion. Despite these growth drivers, high therapy costs and efficacy concerns remain key restraints that could limit adoption, particularly in emerging markets. Meanwhile, expanding applications of cell therapies across oncology, autoimmune diseases, and regenerative medicine present significant opportunities for market growth during the forecast period.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/cell-therapy-market?Juli

Recent Developments:

✅ December 2025: A major biopharma company expanded its cell therapy portfolio by launching a next‐generation allogeneic CAR‐T platform designed to reduce manufacturing time and cost, enabling broader access for oncology patients.

✅ October 2025: A leading academic‐industry consortium announced positive Phase II results for a novel stem cell therapy for heart failure, demonstrating improved cardiac function and quality of life in treated patients.

✅ August 2025: A global health authority updated regulatory guidance to streamline accelerated approval pathways for regenerative cell therapies targeting rare diseases, encouraging clinical innovation and faster time to market.

✅ June 2025: A prominent contract development and manufacturing organization (CDMO) announced the commissioning of a new GMP‐compliant cell therapy production facility, significantly increasing regional manufacturing capacity for autologous and allogeneic cell products.

✅ April 2025: Abeona Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) approved ZEVASKYN (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is the first and only autologous cell-based gene therapy.

✅ March 2025: Bristol Myers Squibb Company announced that the European Commission (EC) approved CAR-T Cell Therapy Breyanzi for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Mergers & Acquisitions:

✅ November 2025: A leading global biopharmaceutical company completed the acquisition of a specialized cell therapy platform developer, strengthening its allogeneic and regenerative therapy portfolio.

✅ September 2025: A major oncology‐focused biotech firm acquired a clinical‐stage cell therapy startup with proprietary engineered T‐cell constructs, accelerating its pipeline expansion into solid tumors.

✅ July 2025: A top contract development and manufacturing organization (CDMO) acquired a regional cell therapy manufacturing facility to expand GMP production capacity for both autologous and allogeneic cell products.

✅ May 2025: A large healthcare conglomerate merged with a stem cell R&D company to enhance its regenerative medicine division and widen its therapeutic offerings in immunotherapy and degenerative disease treatment.

✅ February 2025: A multinational pharmaceutical company completed the acquisition of a gene‐editing/cell therapy hybrid technology firm to integrate next‐generation delivery methods into its cell therapy platforms.

Key Players:

• Gilead Sciences, Inc. - A leading biopharmaceutical company with a strong focus on CAR-T and other advanced cell therapy platforms.

• Novartis AG - A pioneer in allogeneic and autologous cell therapies, known for its Kymriah® CAR-T therapy and ongoing pipeline expansions.

• Vericel Corporation - Specializes in regenerative medicine and autologous cell therapies for musculoskeletal and severe diseases.

• CO.DON GmbH - A German biotech firm focused on cartilage cell therapies and tissue regeneration products.

• Bristol Myers Squibb Company - Global biopharma company with an expanding portfolio of CAR-T and other cellular immunotherapies.

• IOVANCE Biotherapeutics, Inc. - Developer of tumor-infiltrating lymphocyte (TIL)-based cell therapies for oncology applications.

• Dendreon Pharmaceuticals LLC. - Pioneer in immunotherapy and cellular therapeutic products, including Provenge® for prostate cancer.

• Enzyvant Therapeutics GmbH - Focused on developing rare disease-targeted cell and gene therapies.

• CellTrans - Specializes in mesenchymal stem cell therapies for organ transplantation and regenerative medicine.

• Gamida Cell Inc. - Develops innovative cell therapies, including natural killer (NK) cell-based treatments for hematologic malignancies.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=cell-therapy-market?Juli

Market Segmentation:

➥ By Source, the market is categorized into Autologous and Allogeneic cell therapies. Autologous therapies, which use the patient's own cells, account for approximately 55% of the market due to their lower risk of immune rejection and proven clinical success in CAR-T and other personalized therapies. Allogeneic therapies, derived from donor cells, make up around 45% of the market, driven by their potential for off-the-shelf scalability and lower production time compared to autologous approaches.

➥ By Cell Type, the market includes Stem Cells, Immune Cells, and Other Cell Types. Immune cell therapies, such as CAR-T and TIL therapies, represent the largest share at 50%, fueled by widespread adoption in oncology and ongoing clinical developments. Stem cell therapies, including mesenchymal and hematopoietic stem cells, hold approximately 40% of the market, driven by applications in regenerative medicine, hematology, and rare diseases. Other cell types, which include specialized or engineered cells for niche indications, account for the remaining 10% of the market.

➥ By Application, the market is divided into Oncology, Cardiovascular Disorders, Neurological Disorders, and Other Applications. Oncology remains the dominant segment with a 60% market share, as CAR-T therapies and other immune cell treatments are primarily developed for hematologic and solid tumors. Cardiovascular applications represent 15%, driven by regenerative and cell-based therapies targeting heart failure and ischemic injuries. Neurological disorders, such as Parkinson's and spinal cord injuries, account for 10% of the market. Other applications, including autoimmune and rare genetic disorders, contribute the remaining 15%, highlighting emerging opportunities in diverse therapeutic areas.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/cell-therapy-market?Juli

Market Dynamics:

The cell therapy market is being strongly driven by rising research and development activities and increasing regulatory approvals. With a growing demand for disease-modifying treatment options for chronic and untreatable conditions, cell therapies are emerging as personalized, targeted, and potentially curative solutions, particularly in oncology, autoimmune disorders, and rare genetic diseases. Both established biopharmaceutical companies and emerging players are heavily investing in developing innovative cell therapies, which has resulted in multiple approvals based on proven safety and efficacy in clinical trials. For example, in December 2024, the U.S. FDA approved Ryoncil (remestemcel-L-rknd), the first allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients aged 2 months and older. Similarly, in September 2024, Aurion Biotech launched Vyznova (neltependocel) in Japan for the treatment of bullous keratopathy of the cornea, marking the first cell therapy approved in Japan for corneal endothelial disease. These milestones underscore the market potential for emerging cell therapies and indicate that upcoming product launches will continue to fuel growth during the forecast period.

However, high costs of approved cell therapies remain a key restraint for market expansion. Treatments such as CAR-T therapies are priced extremely high, with Yescarta costing approximately USD 424,000 in the United States. Variations in pricing across countries, coupled with limited reimbursement coverage in many regions, restrict patient access and adoption. As affordability plays a crucial role in the uptake of these therapies, the high treatment costs may slow overall market growth despite the strong clinical potential and rising R&D activity in the sector.

Regional Insights:

North America dominates the cell therapy market with a 40% share (USD 2.61 billion in 2024), driven by advanced healthcare infrastructure, strong R&D capabilities, early adoption of innovative therapies, and favorable regulatory frameworks. The U.S. leads the region with widespread clinical trials, multiple FDA-approved cell therapies, and significant investment from biopharmaceutical companies.

Europe accounts for a 25% share (USD 1.63 billion in 2024), supported by well-established healthcare systems, collaborative research networks, and increasing regulatory approvals for cell- and gene-based therapies. Countries such as Germany, the UK, and France are investing heavily in clinical development and commercial-scale manufacturing of cell therapies.

Asia-Pacific is the fastest-growing region, representing a 20% share (USD 1.30 billion in 2024), with a projected CAGR exceeding 24% during 2025-2033. Growth is fueled by rising healthcare investments, government initiatives supporting regenerative medicine, increasing patient awareness, and expanding clinical trials in countries such as China, Japan, and South Korea.

Latin America, the Middle East, and Africa (LAMEA) collectively contribute 15% (USD 0.98 billion in 2024), driven by improving healthcare infrastructure, growing access to advanced treatments, and rising prevalence of chronic diseases. Key markets include Brazil, Mexico, South Africa, and the UAE, where initiatives are underway to expand cell therapy adoption and local clinical capabilities.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.